No Data
Placo 2024 Annual Results Forecast
Pulike Biological Engineering, Inc. (603566.SH): The net profit for 2024 is expected to decrease by 42.70% to 54.16%.
Gelonghui January 17丨Pulike Biological Engineering, Inc. (603566.SH) announced its annual performance forecast for 2024, estimating that the net income attributable to the owners of the parent company will be between 80 million yuan and 100 million yuan, a year-on-year decrease of 42.70% to 54.16%. The company expects the net income attributable to the owners of the parent company, excluding non-recurring gains and losses, to be between 67 million yuan and 87 million yuan, a year-on-year decrease of 43.49% to 56.48%. In 2024, the downstream aquaculture industry is expected to experience a phase of recovery, but demand for veterinary vaccines and chemical drugs remains uncertain.
Pulike Biological Engineering Director to Trim Stake
Pulike Biological Engineering, Inc. (603566.SH): Director and executive Hu Wei intends to reduce Shareholding by no more than 0.8 million shares.
Pulike Biological Engineering, Inc. (603566.SH) issued an announcement that Director and senior management personnel Hu Wei intends to sell 2... due to personal funding needs.
Pulike Biological Engineering Gets Nod for Avian Influenza Vaccine's Registration
Pulike Biological Engineering, Inc. (603566.SH): The Mengbang Express Pet Supply Chain Platform has currently completed initial setup and has started market operation.
On January 7th, Gelonghui reported that Pulike Biological Engineering, Inc. (603566.SH) stated on the investor interaction platform, "Mengbang Kuaiao" is a trademark of related enterprises, which has been authorized for use by the subsidiary Lechong Health for sales activities of related products on the pet supply chain platform. Currently, the Mengbang Kuaiao pet supply chain platform has completed its initial setup and has started market operation.
Benign Growth For Pulike Biological Engineering, Inc. (SHSE:603566) Underpins Stock's 27% Plummet
